The role of TP53 in cervical carcinogenesis

被引:139
作者
Tommasino, M [1 ]
Accardi, R [1 ]
Caldeira, S [1 ]
Dong, W [1 ]
Malanchi, E [1 ]
Smet, A [1 ]
Zehbe, I [1 ]
机构
[1] Deutsch Krebsforschungszentrum, INF 242, D-6900 Heidelberg, Germany
关键词
cervical cancer; cancer; tumor; p53; TP53; human papilloma virus; HPV; E6-mediated p53 inactivation; E6AP; UBE3A;
D O I
10.1002/humu.10178
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Functional loss of the tumor suppressor p53 by alterations in its TP53 gene is a frequent event in cancers of different anatomical regions. Cervical cancer is strongly linked to infection by high-risk human papillomavirus (HPV) types. The viral oncoprotein E6 has the ability to associate with and neutralize the function of p53. E6 interacts with a 100-kDa cellular protein, termed E6 associated protein (E6AP; also called ubiquitin-protein ligase E3A or UBE3A), which functions as an ubiquitin protein ligase. The dimeric complex then binds p53 and E6AP catalyzes multi-ubiquitination and degradation of p53. The ability to promote p53 degradation is an exclusive property of E6 from the high,risk HPV types. Indeed, the low-risk E6 proteins lack this activity, although they can bind p53. Consistent with the E6 function of the high-risk HPV types, the majority of cervical cancer cells have a wild type p53 gene, but the protein levels are strongly decreased. Several independent studies have shown that in a small percentage of cervical tumors the p53 gene is mutated. However, this event appears to be unrelated to the presence or absence of HPV infection and the nature of the tumor.
引用
收藏
页码:307 / 312
页数:6
相关论文
共 61 条
[1]   p53 codon 72 polymorphism and risk of intra-epithelial and invasive cervical neoplasia in Greek women [J].
Agorastos, T ;
Lambropoulos, AF ;
Constantinidis, TC ;
Kotsis, A ;
Bontis, JN .
EUROPEAN JOURNAL OF CANCER PREVENTION, 2000, 9 (02) :113-118
[2]   PREVALENCE OF HUMAN PAPILLOMAVIRUS IN CERVICAL-CANCER - A WORLDWIDE PERSPECTIVE [J].
BOSCH, FX ;
MANOS, MM ;
MUNOZ, N ;
SHERMAN, M ;
JANSEN, AM ;
PETO, J ;
SCHIFFMAN, MH ;
MORENO, V ;
KURMAN, R ;
SHAH, KV ;
ALIHONOU, E ;
BAYO, S ;
MOKHTAR, HC ;
CHICAREON, S ;
DAUDT, A ;
DELOSRIOS, E ;
GHADIRIAN, P ;
KITINYA, JN ;
KOULIBALY, M ;
NGELANGEL, C ;
TINTORE, LMP ;
RIOSDALENZ, JL ;
SARJADI ;
SCHNEIDER, A ;
TAFUR, L ;
TEYSSIE, AR ;
ROLON, PA ;
TORROELLA, M ;
TAPIA, AV ;
WABINGA, HR ;
ZATONSKI, W ;
SYLLA, B ;
VIZCAINO, P ;
MAGNIN, D ;
KALDOR, J ;
GREER, C ;
WHEELER, C .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (11) :796-802
[3]   P53 MUTATIONS IN CERVICAL CARCINOGENESIS LOW-FREQUENCY AND LACK OF CORRELATION WITH HUMAN PAPILLOMAVIRUS STATUS [J].
BUSBYEARLE, RMC ;
STEEL, CM ;
WILLIAMS, ARW ;
COHEN, B ;
BIRD, CC .
BRITISH JOURNAL OF CANCER, 1994, 69 (04) :732-737
[4]   Induction of apoptosis in human papillomavirus-positive cancer cells by peptide aptamers targeting the viral E6 oncoprotein [J].
Butz, K ;
Denk, C ;
Ullmann, A ;
Scheffner, M ;
Hoppe-Seyler, F .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (12) :6693-6697
[5]   CLONAL P53 MUTATION IN PRIMARY CERVICAL-CANCER - ASSOCIATION WITH HUMAN-PAPILLOMAVIRUS-NEGATIVE TUMORS [J].
CROOK, T ;
WREDE, D ;
TIDY, JA ;
MASON, WP ;
EVANS, DJ ;
VOUSDEN, KH .
LANCET, 1992, 339 (8801) :1070-1073
[6]  
CROOK T, 1991, ONCOGENE, V6, P873
[7]   p53 mutations are rare events in recurrent cervical cancer [J].
Denk, C ;
Butz, K ;
Schneider, A ;
Dürst, M ;
Hoppe-Seyler, F .
JOURNAL OF MOLECULAR MEDICINE-JMM, 2001, 79 (5-6) :283-288
[8]  
FUJITA M, 1992, CANCER RES, V52, P5323
[9]   GENETIC ALTERATIONS OF THE TP53 GENE, P53 PROTEIN EXPRESSION AND HPV INFECTION IN PRIMARY CERVICAL CARCINOMAS [J].
HELLAND, A ;
HOLM, R ;
KRISTENSEN, G ;
KAERN, J ;
KARLSEN, F ;
TROPE, C ;
NESLAND, JM ;
BORRESEN, AL .
JOURNAL OF PATHOLOGY, 1993, 171 (02) :105-114
[10]  
Helland Å, 1998, NATURE, V396, P530, DOI 10.1038/25034